Spiral Therapeutics Raises $27M in Series B Funding, Partners with Advanced Bionics

The financing will support development of Spiral's pipeline of inner ear disorder treatments, including its lead program SPT-2101 for Ménière's disease.

Apr. 14, 2026 at 12:53pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life image of a sleek, modern cochlear implant device made of polished metal and glass, floating elegantly on a clean, white background with dramatic studio lighting and deep shadows, conveying a sense of precision and innovation in medical technology.A new strategic partnership between Spiral Therapeutics and cochlear implant leader Advanced Bionics aims to unlock the potential of local drug delivery to improve outcomes for implant recipients.South San Francisco Today

Spiral Therapeutics, a clinical-stage biotech company focused on inner ear disorders, has closed a $27 million Series B financing round led by Gund Investment. The round includes new strategic investments from cochlear implant maker Advanced Bionics and a major global pharmaceutical company, as well as continued participation from existing investors Ferring Ventures and Uni-Bio Science Group. Concurrent with the financing, Spiral also announced a strategic R&D collaboration with Advanced Bionics to explore drug delivery at the time of cochlear implantation.

Why it matters

The funding and partnership represent significant validation for Spiral's platform and pipeline, which aim to address the significant unmet need in inner ear disorders - an area that has historically been underinvested and underinnovated in the pharmaceutical industry. Spiral's lead program SPT-2101 has shown promise in treating Ménière's disease, a debilitating balance disorder, and the company is preparing for a registrational trial.

The details

The $27 million Series B round was led by Gund Investment, with new strategic investments from cochlear implant maker Advanced Bionics and a major global pharmaceutical company. Existing investors Ferring Ventures, Uni-Bio Science Group, and others also participated. Concurrent with the financing, Spiral entered into a strategic R&D collaboration with Advanced Bionics to explore sustained local drug delivery at the time of cochlear implantation.

  • Spiral Therapeutics announced the closing of its $27 million Series B financing on April 14, 2026.

The players

Spiral Therapeutics

A clinical-stage biotechnology company focused on developing novel therapies for inner ear disorders, including hearing loss and balance disorders. The company's MICS™ drug delivery platform is designed to enable minimally invasive, precise and durable exposure of therapeutics to the cochlea.

Advanced Bionics

A global leader in cochlear implant technology that has joined Spiral's Series B financing as a new strategic investor. The companies have also entered into a strategic R&D collaboration to explore sustained local drug delivery at the time of cochlear implantation.

Gund Investment

The lead investor in Spiral Therapeutics' $27 million Series B financing round.

Ferring Ventures

An existing investor that continued to participate in Spiral Therapeutics' Series B financing.

Uni-Bio Science Group

An existing investor that continued to participate in Spiral Therapeutics' Series B financing.

Got photos? Submit your photos here. ›

What they’re saying

“This financing is a major milestone for Spiral. It brings Advanced Bionics on as a strategic partner, welcomes Gund Investment as our Series B lead, and reinforces the continued support of our existing investors.”

— Hugo Peris, Founder and CEO of Spiral Therapeutics

What’s next

Spiral is preparing to initiate a registrational clinical trial for its lead program SPT-2101, which has shown promise in treating Ménière's disease. The company also plans to advance its broader pipeline of inner ear disorder treatments enabled by its MICS™ drug delivery platform.

The takeaway

Spiral Therapeutics' successful Series B financing and strategic partnership with Advanced Bionics highlight the growing attention and investment in addressing the significant unmet need for innovative treatments in the historically underserved inner ear disorders space. The company's differentiated platform and pipeline position it well to lead the charge in developing new therapies for conditions like hearing loss and balance disorders.